ReviewCurrent opinion in allergy and clinical immunology2016
Regulation of airway inflammation by Siglec-8 and Siglec-9 sialoglycan ligand expression.
Review in Current opinion in allergy and clinical immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 35 citations in OpenAlex.
- Supplementing Glucose Intake Reverses the Inflammation Induced by a High-Fat Diet by Increasing the Expression of Siglec-E Ligands on Erythrocytes.Inflammation · 2024Article
- Computationally guided conversion of the specificity of E-selectin to mimic that of Siglec-8.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Targetable pathogenic mechanisms in nasal polyposis.International forum of allergy & rhinology · 2021Review
- Review
- Sialic acid-binding immunoglobulin-like lectins (Siglecs) detect self-associated molecular patterns to regulate immune responses.Cellular and molecular life sciences : CMLS · 2020Review
- The Role of Heat Shock Protein 70 kDa in Asthma.Journal of asthma and allergy · 2020Review
- The Roles of Siglec7 and Siglec9 on Natural Killer Cells in Virus Infection and Tumour Progression.Journal of immunology research · 2020Review
- Asthma and Chronic Rhinosinusitis: Diagnosis and Medical Management.Medical sciences (Basel, Switzerland) · 2019Review
- Article
- Immunomodulators in chronic rhinosinusitis.World journal of otorhinolaryngology - head and neck surgery · 2018Review
- Precision Medicine in Chronic Rhinosinusitis with Nasal Polyps.Current allergy and asthma reports · 2018Review
- Contemporary Pharmacotherapy for Allergic Rhinitis and Chronic Rhinosinusitis.Otolaryngologic clinics of North America · 2017Review
- Siglec-8 and Siglec-9 binding specificities and endogenous airway ligand distributions and properties.Glycobiology · 2017Article
- Recent advances in understanding eosinophil biology.F1000Research · 2017Review
- A Review of Classification Schemes for Chronic Rhinosinusitis with Nasal Polyposis Endotypes.Laryngoscope investigative otolaryngology · 2016Review
- Glycobiology simplified: diverse roles of glycan recognition in inflammation.Journal of leukocyte biology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
purpose of reviewInflammatory cells involved in the allergic response, including eosinophils, mast cells, basophils, and neutrophils, express sialoglycan-binding proteins such as Siglec-8 and Siglec-9, which inhibit cell function and survival. The purpose of this review is to briefly discuss the biology of these siglecs and their ligands and consider their potential impact in pathology and treatment of chronic rhinosinusitis (CRS). RECENT
findingsRecent studies demonstrate the presence of ligands for Siglec-8 and Siglec-9 in sinonasal tissue from patients with CRS as well as healthy patients, suggesting that the immunoregulatory functions of siglecs may be triggered in sinus tissue in health and disease. SUMMARY: Ligands for Siglec-8 and Siglec-9 may regulate the function of eosinophils, mast cells, neutrophils, and other cells in sinus mucosa. Therapeutic strategies that activate the anti-inflammatory effects of siglecs may dampen inflammation and disease in CRS patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.